At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 285 enrolled
Drug / intervention
50 mg P005672-HCl +2 moredrug
Likely dose
50 mg P005672-HClfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of a Novel Tetracycline Compared to Placebo in the Treatment of Facial Acne Vulgaris, Study PR-10411
In Brief
A Phase 2 clinical trial evaluating 50 mg P005672-HCl, Placebo, and 1 other intervention for Acne Vulgaris. Completed, enrolled 285 participants across 38 sites.
Detailed Summary
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
CollaboratorsAllergan
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartJun 2012
Primary CompletionNov 2012
Study CompletionJan 2013
TodayJul 2026
First PostedJun 26, 2012
Enrollment StartJun 30, 2012
Primary CompletionNov 16, 2012
Study CompletionJan 31, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.0 years ago
Interventions
50 mg P005672-HCldrug
P005672-HCl administered as an oral capsule(s) once daily
Placebodrug
Dose-matched Placebo capsule administered as an oral capsule(s) once daily
100 mg P005672-HCldrug
P005672-HCl administered as an oral capsule(s) once daily